Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aspira Women's Health Inc.AWH · Entity 7871 | Director | March 19, 2021 | March 23, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aspira Women's Health Inc.
Report date March 19, 2021 · Filed March 23, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 171,521 |
Reported balance
After 2021-03-19 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2021-03-19 · Grant · Acquired 4,031 · Balance 171,521 F1: The shares of common stock represent restricted stock units with contingent right to receive one share of common stock of Aspira Women's Health Inc. for each restricted stock unit. The restricted stock units will vest in two equal installments on April 1, 2021 and June 1, 2021. F2: Total reflects the adjustment of 17,528 shares of common stock previously reported as part of a restricted stock unit grant made on March 19, 2020. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of common stock represent restricted stock units with contingent right to receive one share of common stock of Aspira Women's Health Inc. for each restricted stock unit. The restricted stock units will vest in two equal installments on April 1, 2021 and June 1, 2021.
F2: Total reflects the adjustment of 17,528 shares of common stock previously reported as part of a restricted stock unit grant made on March 19, 2020.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 19, 2021 Filed Mar 23, 2021 21:15 UTC | Aspira Women's Health Inc. AWH · Entity 7871 | GrantCommon Stock | 4,031 | $0.00 | $0.00 |
DisclosureSEC source: 0001255627-21-000001 · primary_doc.xml · nonDerivative · entry 1 SCHREIBER DAVID · CIK 0001255627 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,521 F1 · shares: The shares of common stock represent restricted stock units with contingent right to receive one share of common stock of Aspira Women's Health Inc. for each restricted stock unit. The restricted stock units will vest in two equal installments on April 1, 2021 and June 1, 2021. F2 · balance_after: Total reflects the adjustment of 17,528 shares of common stock previously reported as part of a restricted stock unit grant made on March 19, 2020. Read SEC document |
| September 08, 2020 Filed Sep 10, 2020 21:35 UTC | Aspira Women's Health Inc. AWH · Entity 7871 | SaleCommon Stock | 50,000 | $2.78 | $139,000.00 |
DisclosureSEC source: 0001255627-20-000002 · primary_doc.xml · nonDerivative · entry 1 SCHREIBER DAVID · CIK 0001255627 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,018 F1 · shares: The proceeds are intended to cover tax liability for restricted stock units of Aspira Women's Health Inc. received in 2020. F2 · price: The sale reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $2.75 to $2.85 per share. The reporting person undertakes to provide to Aspira Women's Health Inc., any security holder of Aspira Women's Health Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| March 19, 2020 Filed Mar 23, 2020 21:08 UTC | Aspira Women's Health Inc. VRML · Entity 7871 | GrantCommon Stock | 70,113 | $0.00 | $0.00 |
DisclosureSEC source: 0001255627-20-000001 · primary_doc.xml · nonDerivative · entry 1 SCHREIBER DAVID · CIK 0001255627 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,018 F1 · shares: The shares of common stock represent restricted stock units with contingent right to receive one share of common stock of Vermillion, Inc. for each restricted stock unit. The restricted stock units will vest in four equal installments on April 1, 2020, June 1, 2020, September 1, 2020 and December 1, 2020. Read SEC document |
| June 03, 2019 Filed Jun 4, 2019 23:07 UTC | Aspira Women's Health Inc. VRML · Entity 7871 | SaleCommon Stock | 10,000 | $1.10 | $11,000.00 |
DisclosureSEC source: 0001255627-19-000003 · primary_doc.xml · nonDerivative · entry 1 SCHREIBER DAVID · CIK 0001255627 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,905 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| March 26, 2019 Filed Mar 28, 2019 22:46 UTC | Aspira Women's Health Inc. VRML · Entity 7871 | GrantCommon Stock | 37,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001255627-19-000002 · primary_doc.xml · nonDerivative · entry 1 SCHREIBER DAVID · CIK 0001255627 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,905 F1 · shares: The shares of common stock represent restricted stock units with contingent right to receive one share of common stock of Vermillion, Inc. for each restricted stock unit. The restricted stock units will vest in four equal installments on April 1, 2019, June 1, 2019, September 1, 2019 and December 1, 2019. Read SEC document |
| March 07, 2019 Filed Mar 11, 2019 20:20 UTC | Aspira Women's Health Inc. VRML · Entity 7871 | SaleCommon Stock, par value $0.001 per share | 30,000 | $1.00 | $30,000.00 |
DisclosureSEC source: 0001255627-19-000001 · primary_doc.xml · nonDerivative · entry 1 SCHREIBER DAVID · CIK 0001255627 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,405 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| April 13, 2018 Filed Apr 17, 2018 20:07 UTC | Aspira Women's Health Inc. VRML · Entity 7871 | GrantCommon Stock | 79,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001255627-18-000001 · primary_doc.xml · nonDerivative · entry 1 SCHREIBER DAVID · CIK 0001255627 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,405 F1 · shares: The shares of common stock represent restricted stock units with contingent right to receive one share of common stock of Vermillion, Inc. for each restricted stock unit. 50% of the restricted stock units will vest on June 1, 2018, 25% of the restricted stock units will vest on September 1, 2018 and 25% of the restricted stock units will vest on December 1, 2018. Read SEC document |
| March 23, 2017 Filed Mar 27, 2017 20:56 UTC | Aspira Women's Health Inc. VRML · Entity 7871 | GrantCommon Stock | 26,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001255627-17-000001 · primary_doc.xml · nonDerivative · entry 1 SCHREIBER DAVID · CIK 0001255627 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,205 F1 · shares: The shares of common stock represent restricted stock units with contingent right to receive one share of common stock of Vermillion, Inc. for each restricted stock unit. 50% of the restricted stock units will vest on June 1, 2017, 25% of the restricted stock units will vest on September 1, 2017 and 25% of the restricted stock units will vest on December 1, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.